# Erlotinib and Temsirolimus for Solid Tumors

> **NCT00770263** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 46 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT00770263
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770263, "Erlotinib and Temsirolimus for Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00770263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*